Shots:

• The collaboration will combine Microsoft’s computational services, cloud, and AI with Novo Nordisk’s drug discovery, development, and data science capabilities to accelerate drug discovery and development. The collaboration will also accelerate Novo Nordisk’s R&D by using both companies’ expertise
• In the first situation, AI will be used to automatically summarize and analysis of information from a wide array of sources to gain novel scientific insights
• The companies will also use AI to develop models that can predict a person’s risk of developing atherosclerosis, identify biomarkers associated with the disease along with the drug targets

Ref:  Globenewswire | Image: Novo Nordisk